Waldenstrom Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies

被引：5

作者：

Boutilier, Ava J. ^{[1
]}

Huang, Lina ^{[2
]}

Elsawa, Sherine F. ^{[1
]}

机构：

[1] Univ New Hampshire, Dept Mol Cellular & Biomed Sci, Durham, NH 03824 USA

[2] Phillips Exeter Acad, Exeter, NH 03833 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 19期

关键词：

Waldenstrom macroglobulinemia; B-cell lymphoma; non-Hodgkin's; bone marrow microenvironment; disease progression; targeted therapy; NF-KAPPA-B; BONE-MARROW MICROENVIRONMENT; PHASE-II TRIAL; HYPOXIA PROMOTES DISSEMINATION; EPHRIN-A1; MESSENGER-RNA; SPLEEN TYROSINE KINASE; MULTIPLE-MYELOMA; MYD88; L265P; IN-VITRO; INHIBITOR EVEROLIMUS;

D O I：

10.3390/ijms231911145

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Waldenstrom macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenstrom macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.

引用

页数：20

共 146 条

[61] IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia [J].

Hodge, Lucy S. ;

Ziesmer, Steve C. ;

Yang, Zhi Zhang ;

Secreto, Frank J. ;

Gertz, Morie A. ;

Novak, Anne J. ;

Ansell, Stephen M. .

BLOOD, 2012, 120 (18) :3774-3782

[62] Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenstrom's Macroglobulinemia [J].

Ioakimidis, Leukothea ;

Patterson, Christopher J. ;

Hunter, Zachary R. ;

Soumerai, Jacob D. ;

Manning, Robert J. ;

Turnbull, Barry ;

Sheehy, Patricia ;

Treon, Steven P. .

CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (01) :62-66

[63] Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma [J].

Ishikawa, Masashi ;

Miyahara, Ryo ;

Sonobe, Makoto ;

Horiuchi, Marika ;

Mennju, Toshi ;

Nakayama, Ei ;

Kobayashi, Masashi ;

Kikuchi, Ryutaro ;

Kitamura, Jiro ;

Imamura, Naoto ;

Huang, Cheng-Long ;

Date, Hiroshi .

LUNG CANCER, 2012, 76 (03) :431-438

[64] Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia [J].

Jalali, Shahrzad ;

Price-Troska, Tammy ;

Paludo, Jonas ;

Villasboas, Jose ;

Kim, Hyo-Jin ;

Yang, Zhi-Zhang ;

Novak, Anne J. ;

Ansell, Stephen M. .

BLOOD ADVANCES, 2018, 2 (15) :1985-1997

[65] Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia [J].

Janes, M. R. ;

Vu, C. ;

Mallya, S. ;

Shieh, M. P. ;

Limon, J. J. ;

Li, L-S ;

Jessen, K. A. ;

Martin, M. B. ;

Ren, P. ;

Lilly, M. B. ;

Sender, L. S. ;

Liu, Y. ;

Rommel, C. ;

Fruman, D. A. .

LEUKEMIA, 2013, 27 (03) :586-594

[66] Diagnosis and Management of Waldenstrom Macroglobulinemia Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 [J].

Kapoor, Prashant ;

Ansell, Stephen M. ;

Fonseca, Rafael ;

Chanan-Khan, Asher ;

Kyle, Robert A. ;

Kumar, Shaji K. ;

Mikhael, Joseph R. ;

Witzig, Thomas E. ;

Mauermann, Michelle ;

Dispenzieri, Angela ;

Ailawadhi, Sikander ;

Stewart, A. Keith ;

Lacy, Martha Q. ;

Thompson, Carrie A. ;

Buadi, Francis K. ;

Dingli, David ;

Morice, William G. ;

Go, Ronald S. ;

Jevremovic, Dragan ;

Sher, Taimur ;

King, Rebecca L. ;

Braggio, Esteban ;

Novak, Ann ;

Roy, Vivek ;

Ketterling, Rhett P. ;

Greipp, Patricia T. ;

Grogan, Martha ;

Micallef, Ivana N. ;

Bergsagel, P. Leif ;

Colgan, Joseph P. ;

Leung, Nelson ;

Gonsalves, Wilson I. ;

Lin, Yi ;

Inwards, David J. ;

Hayman, Suzanne R. ;

Nowakowski, Grzegorz S. ;

Johnston, Patrick B. ;

Russell, Steven J. ;

Markovic, Svetomir N. ;

Zeldenrust, Steven R. ;

Hwa, Yi L. ;

Lust, John A. ;

Porrata, Luis F. ;

Habermann, Thomas M. ;

Rajkumar, Vincent ;

Gertz, Morie A. ;

Reeder, Craig B. .

JAMA ONCOLOGY, 2017, 3 (09) :1257-1265

[67] Rituximab A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma [J].

Keating, Gillian M. .

DRUGS, 2010, 70 (11) :1445-1476

[68] LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice [J].

Keyes, KA ;

Mann, L ;

Sherman, M ;

Galbreath, E ;

Schirtzinger, L ;

Ballard, D ;

Chen, YF ;

Iversen, P ;

Teicher, BA .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) :133-140

[69] Development of BTK inhibitors for the treatment of B-cell malignancies [J].

Kim, Hyung-Ook .

ARCHIVES OF PHARMACAL RESEARCH, 2019, 42 (02) :171-181

[70] Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenstrom Macroglobulinemia [J].

Kuiatse, Isere ;

Baladandayuthapani, Veerabhadran ;

Lin, Heather Y. ;

Thomas, Sheeba K. ;

Bjorklund, Chad C. ;

Weber, Donna M. ;

Wang, Michael ;

Shah, Jatin J. ;

Zhang, Xing-Ding ;

Jones, Richard J. ;

Ansell, Stephen M. ;

Yang, Guang ;

Treon, Steven P. ;

Orlowski, Robert Z. .

CLINICAL CANCER RESEARCH, 2015, 21 (11) :2538-2545

← 2 3 4 5 6 7 8 9 10 11 →